{"id":46805,"date":"2022-08-01T21:01:42","date_gmt":"2022-08-01T19:01:42","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/amyloid-precursor-protein-secretase-inhibitors-pipeline-market-report-2022-comprehensive-insights-about-5-companies-and-5-pipeline-drugs-researchandmarkets-com\/"},"modified":"2022-08-01T21:01:42","modified_gmt":"2022-08-01T19:01:42","slug":"amyloid-precursor-protein-secretase-inhibitors-pipeline-market-report-2022-comprehensive-insights-about-5-companies-and-5-pipeline-drugs-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/amyloid-precursor-protein-secretase-inhibitors-pipeline-market-report-2022-comprehensive-insights-about-5-companies-and-5-pipeline-drugs-researchandmarkets-com\/","title":{"rendered":"Amyloid Precursor Protein Secretase Inhibitors Pipeline Market Report 2022: Comprehensive Insights About 5+ Companies and 5+ Pipeline Drugs – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Amyloid precursor protein secretase inhibitors – Pipeline Insight, 2022”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nThis “Amyloid precursor protein secretase inhibitors – Pipeline Insight, 2022” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Amyloid precursor protein secretase inhibitors pipeline landscape.\n<\/p>\n

\nIt covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.\n<\/p>\n

\nAmyloid precursor protein secretase inhibitors: Overview<\/strong>\n<\/p>\n

\nAccording to the beta-amyloid (Abeta) hypothesis, compounds that inhibit gamma-secretase, the pivotal enzyme that generates Abeta, are potential therapeutics for Alzheimer’s disease (AD). Studies in both transgenic and non-transgenic animal models of AD have indicated that gamma-secretase inhibitors, administered by the oral route, are able to lower brain Abeta concentrations. Inhibition of gamma-secretase presents a direct target for lowering A\u03b2 production in the brain as a therapy for Alzheimer’s disease (AD).\n<\/p>\n

\nReport Highlights<\/strong>\n<\/p>\n

\nThe companies and academics are working to assess challenges and seek opportunities that could influence Amyloid precursor protein secretase inhibitors R&D. The therapies under development are focused on novel approaches for Amyloid precursor protein secretase inhibitors.\n<\/p>\n

\nAmyloid precursor protein secretase inhibitors: Emerging Drugs Chapters<\/strong>\n<\/p>\n

\nThis segment of the Amyloid precursor protein secretase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.\n<\/p>\n

\nAmyloid precursor protein secretase inhibitors: Emerging Drugs<\/strong>\n<\/p>\n

\nNirogacestat: SpringWorks Therapeutics\n<\/p>\n

\nNirogacestat is an oral, selective, small molecule, gamma secretase inhibitor (GSI) in Phase 3 clinical development for patients with desmoid tumors. Gamma secretase is a protease complex that cleaves, or divides, multiple transmembrane protein complexes, including Notch, which, when dysregulated, can play a role in activating pathways that contribute to desmoid tumor growth.\n<\/p>\n

\nIt is currently in Phase III stage of development for the treatment of Desmoid tumors and is being developed by SpringWorks Therapeutics.\n<\/p>\n

\nAL101: Ayala Pharmaceuticals\n<\/p>\n

\nAL101 is a novel, injectable, potent and selective small molecule gamma secretase inhibitor (GSI). The US Food and Drug Administration (FDA) granted Orphan Drug Designation and Fast Track Designation to AL101 for the potential treatment of Adenoid cystic carcinoma (ACC). It is currently in Phase II stage of development for the treatment of Amyloid precursor protein secretase inhibitors and is being developed by Ayala Pharmaceuticals.\n<\/p>\n

\nAmyloid precursor protein secretase inhibitors: Therapeutic Assessment<\/strong>\n<\/p>\n

\nThis segment of the report provides insights about the different Amyloid precursor protein secretase inhibitors drugs segregated based on following parameters that define the scope of the report.\n<\/p>\n

\nMajor Players working on Amyloid precursor protein secretase inhibitors<\/strong>\n<\/p>\n

\nThere are approx. 5+ key companies which are developing the Amyloid precursor protein secretase inhibitors. The companies which have their Amyloid precursor protein secretase inhibitors drug candidates in the most advanced stage, i.e. Phase III include, SpringWorks Therapeutics.\n<\/p>\n

\nPhases<\/strong>\n<\/p>\n

\nThis report covers around 5+ products under different phases of clinical development like<\/strong>\n<\/p>\n